0000000000745127

AUTHOR

Philippe Genne

showing 2 related works from this author

Phase 0/1 of Positron Emission Tomography (PET) imaging agent [18F]-ODS2004436 as a marker of EGFR mutation in patients with non-small cell lung canc…

2018

e24184Background: Multiple EGFR tyrosine kinase inhibitors (TKIs) are approved for treatment of NSCLC harboring EGFR activating mutations or secondary TKIs resistant mutation. We evaluate a new PET...

Cancer Research[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingnon-small cell lung cancer (NSCLC)[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciences0302 clinical medicinemedicineIn patientComputingMilieux_MISCELLANEOUSmedicine.diagnostic_testbusiness.industryPet imagingmedicine.diseaseEGFR Tyrosine Kinase Inhibitorsrespiratory tract diseases3. Good health[SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/ImagingOncologyEgfr mutationPositron emission tomography030220 oncology & carcinogenesisMutation (genetic algorithm)Cancer researchbusiness030215 immunology
researchProduct

Temozolomide and radiotherapy antitumor efficacy evaluation with magnetic resonance imaging and proton magnetic resonance spectroscopy in human gliom…

2008

International audience

Cancer ResearchHuman gliomaTemozolomideMaterials sciencemedicine.diagnostic_test[ INFO.INFO-IM ] Computer Science [cs]/Medical Imagingbusiness.industrymedicine.medical_treatment[INFO.INFO-IM] Computer Science [cs]/Medical ImagingMagnetic resonance imagingProton magnetic resonance3. Good health030218 nuclear medicine & medical imagingRadiation therapy03 medical and health sciences0302 clinical medicineOncologymedicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingNuclear medicinebusinessSpectroscopyComputingMilieux_MISCELLANEOUSmedicine.drug
researchProduct